Net sales grew 13.8% year-over-year in Q2 2026, led by strong demand for high-value products, especially in Biologics and GLP-1. Operating profit and margins improved, while a cyberattack impacted the West Vantage segment. The company completed a major asset sale and launched a new $1B share repurc…
Net sales grew 13.8% year-over-year in Q2 2026, led by strong demand for high-value products, especially in Biologics and GLP-1. Operating profit and margins improved, while a cyberattack impacted the West Vantage segment. The company completed a major asset sale and launched a new $1B share repurchase program.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
